Q-omics provides the consensus-scored ZNF423 profile across patient tissues and cancer cell-line models. ZNF423 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ZNF423 is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, ZNF423 RNA expression shows 19,369 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight UCS, LUAD, and CCRCC as cancer lineages where ZNF423 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF423 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF423 survival associations across molecular data types. ZNF423 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF423 RNA expression–survival associations across cancer types. High ZNF423 expression shows favorable associations in UCS, KIRC, ACC, HNSC, BRCA and LGG. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for ZNF423 RNA expression.
This table summarizes ZNF423 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF423. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF423 shows lower tumor expression in LUAD, LUSC, THCA, COAD and KICH and higher tumor expression in LIHC. The LUAD box plot shows higher ZNF423 RNA expression in normal versus tumor tissue (log2 FC = −1.255, t-test p < 0.001).
This table shows molecular features associated with ZNF423 in patient tissues and cancer cell lines. In patient samples, ZNF423 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF423 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
